## Yakeel T Quiroz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2257780/publications.pdf

Version: 2024-02-01

186209 85498 5,821 133 28 71 citations h-index g-index papers 153 153 153 6671 docs citations times ranked citing authors all docs

#	Article	lF	CITATIONS
1	Waning locus coeruleus integrity precedes cortical tau accrual in preclinical autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2023, 19, 169-180.	0.4	11
2	Working Group Recommendations for the Practice of Teleneuropsychology in Latin America. Archives of Clinical Neuropsychology, 2022, 37, 553-567.	0.3	12
3	Subjective Cognitive Decline and its Relation to Verbal Memory and Sex in Cognitively Unimpaired Individuals from a Colombian Cohort with Autosomal-Dominant Alzheimer's Disease. Journal of the International Neuropsychological Society, 2022, 28, 541-549.	1.2	7
4	Initial investigation of test-retest reliability of home-to-home teleneuropsychological assessment in healthy, English-speaking adults. Clinical Neuropsychologist, 2022, 36, 2153-2167.	1.5	15
5	Current directions in tau research: Highlights from Tau 2020. Alzheimer's and Dementia, 2022, 18, 988-1007.	0.4	42
6	Sex differences in cognitive resilience in preclinical autosomalâ€dominant Alzheimer's disease carriers and nonâ€carriers: Baseline findings from the API ADAD Colombia Trial. Alzheimer's and Dementia, 2022, 18, 2272-2282.	0.4	10
7	Testing the amyloid cascade hypothesis: Prevention trials in autosomal dominant Alzheimer disease. Alzheimer's and Dementia, 2022, 18, 2687-2698.	0.4	13
8	Addressing the disparities in dementia risk, early detection and care in Latino populations: Highlights from the second Latinos & Samp; Alzheimer's Symposium. Alzheimer's and Dementia, 2022, 18, 1677-1686.	0.4	16
9	Racial and socioeconomic status differences in stress, posttraumatic growth, and mental health in an older adult cohort during the COVID-19 pandemic. EClinicalMedicine, 2022, 45, 101343.	3.2	21
10	Lower novelty-related locus coeruleus function is associated with ${\rm A\hat{I}^2}$ -related cognitive decline in clinically healthy individuals. Nature Communications, 2022, 13, 1571.	5.8	32
11	A cultural approach to dementia — insights from US Latino and other minoritized groups. Nature Reviews Neurology, 2022, 18, 307-314.	4.9	16
12	Consideration of sex and gender in Alzheimer's disease and related disorders from a global perspective. Alzheimer's and Dementia, 2022, 18, 2707-2724.	0.4	35
13	Amyloid-β and tau pathologies relate to distinctive brain dysconnectomics in preclinical autosomal-dominant Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2113641119.	3.3	26
14	Olfactory Function and Markers of Brain Pathology in Non-Demented Individuals with Autosomal Dominant Alzheimer's Disease. Journal of Alzheimer's Disease, 2022, 88, 721-729.	1.2	1
15	White matter hyperintensities are a prominent feature of autosomalÂdominant Alzheimer's disease that emerge prior to dementia. Alzheimer's Research and Therapy, 2022, 14, .	3.0	12
16	Distinct tau neuropathology and cellular profiles of an APOE3 Christchurch homozygote protected against autosomal dominant Alzheimer's dementia. Acta Neuropathologica, 2022, 144, 589-601.	3.9	32
17	Feasibility Trial of a Mind–Body Activity Pain Management Program for Older Adults With Cognitive Decline. Gerontologist, The, 2021, 61, 1326-1337.	2.3	22
18	Development of a Novel Mind–Body Activity and Pain Management Program for Older Adults With Cognitive Decline. Gerontologist, The, 2021, 61, 449-459.	2.3	13

#	Article	IF	CITATIONS
19	Normative data stratified by age and education for a Spanish neuropsychological test battery: Results from the Colombian Alzheimer's prevention initiative registry. Applied Neuropsychology Adult, 2021, 28, 230-244.	0.7	12
20	Association Between Visual Memory and <i>In Vivo</i> Amyloid and Tau Pathology in Preclinical Autosomal Dominant Alzheimer's Disease. Journal of the International Neuropsychological Society, 2021, 27, 47-55.	1.2	6
21	Retinal Imaging Findings in Carriers With <i>PSEN1</i> Disease Before Onset of Cognitive Symptoms. JAMA Ophthalmology, 2021, 139, 49.	1.4	11
22	Dementia in Latin America: Paving the way toward a regional action plan. Alzheimer's and Dementia, 2021, 17, 295-313.	0.4	68
23	PET evidence of preclinical cerebellar amyloid plaque deposition in autosomal dominant Alzheimer's disease-causing Presenilin-1 E280A mutation carriers. Neurolmage: Clinical, 2021, 31, 102749.	1.4	8
24	Longitudinal amyloid and tau accumulation in autosomal dominant Alzheimer's disease: findings from the Colombia-Boston (COLBOS) biomarker study. Alzheimer's Research and Therapy, 2021, 13, 27.	3.0	34
25	Cortical thickness across the lifespan in a Colombian cohort with autosomalâ€dominant Alzheimer's disease: A crossâ€sectional study. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12233.	1.2	2
26	Associations between plasma neurofilament light, in vivo brain pathology, and cognition in nonâ€demented individuals with autosomalâ€dominant Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, 813-821.	0.4	8
27	Associations between subregional thalamic volume and brain pathology in autosomal dominant Alzheimer's disease. Brain Communications, 2021, 3, fcab101.	1.5	11
28	Dementia caregiving across Latin America and the Caribbean and brain health diplomacy. The Lancet Healthy Longevity, 2021, 2, e222-e231.	2.0	33
29	The impact of COVID-19 on the well-being and cognition of older adults living in the United States and Latin America. EClinicalMedicine, 2021, 35, 100848.	3.2	22
30	Stress, resilience, and coping strategies in a sample of community-dwelling older adults during COVID-19. Journal of Psychiatric Research, 2021, 138, 176-185.	1.5	53
31	Specific Abnormalities in White Matter Pathways as Interface to Small Vessels Disease and Cognition in Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy Individuals. Brain Connectivity, 2021, , .	0.8	1
32	Global Cardiovascular Risk Profile and Cerebrovascular Abnormalities in Presymptomatic Individuals with CADASIL or Autosomal Dominant Alzheimer's Disease. Journal of Alzheimer's Disease, 2021, 82, 841-853.	1.2	2
33	Disparities by Race and Ethnicity Among Adults Recruited for a Preclinical Alzheimer Disease Trial. JAMA Network Open, 2021, 4, e2114364.	2.8	68
34	Sex Differences in Cognitive Abilities Among Children With the Autosomal Dominant Alzheimer Disease Presenilin 1 E280A Variant From a Colombian Cohort. JAMA Network Open, 2021, 4, e2121697.	2.8	3
35	Neuroticism Is Associated with Tau Pathology in Cognitively Unimpaired Individuals with Autosomal Dominant Alzheimer's Disease. Journal of Alzheimer's Disease, 2021, 82, 1809-1822.	1.2	10
36	The cortical origin and initial spread of medial temporal tauopathy in Alzheimerâ $\in$ <sup>M</sup> s disease assessed with positron emission tomography. Science Translational Medicine, 2021, 13, .	5 <b>.</b> 8	111

#	Article	IF	Citations
37	Selfâ€reported OSA risk, but not daytime sleepiness, is related to memory decline in autosomal dominant Alzheimer's disease: Preliminary findings from the COLBOS biomarker study. Alzheimer's and Dementia, 2021, 17, .	0.4	0
38	Clinical characterization of Colombian families with frontotemporal dementia due to the MAPT P397S mutation. Alzheimer's and Dementia, 2021, $17$ , .	0.4	1
39	Amyloidâ€Î² and tau pathologies relate to distinctive brain dysconnectomics in autosomalâ€dominant Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, .	0.4	2
40	Clinical and biological heterogeneity in autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, .	0.4	0
41	Greater psychological resilience during the COVIDâ $\in$ 19 pandemic is associated with lower tau burden in cognitively unimpaired individuals. Alzheimer's and Dementia, 2021, 17, .	0.4	0
42	Associations between plasma pâ€tau217, in vivo brain pathology and cognition in individuals with autosomalâ€dominant Alzheimer's disease: Findings from the Colombiaâ€Boston (COLBOS) biomarker study. Alzheimer's and Dementia, 2021, 17, .	0.4	0
43	Amygdala tau pathology in preclinical autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, .	0.4	0
44	The impact of COVIDâ€19 on the wellâ€being and cognition of older adults living in the United States and Latin America. Alzheimer's and Dementia, 2021, 17, .	0.4	1
45	Multimodal neuroimaging biomarkers of Alzheimer's disease in older adults with depression: Preliminary findings from a pilot cohort. Alzheimer's and Dementia, 2021, 17, .	0.4	0
46	Locus coeruleus integrity predicts tau accumulation and memory dysfunction in autosomal dominant Alzheimer's disease Alzheimer's and Dementia, 2021, 17 Suppl 3, e052664.	0.4	0
47	Sex differences in blood-based biomarkers in individuals with autosomal dominant Alzheimer's disease Alzheimer's and Dementia, 2021, 17 Suppl 3, e055011.	0.4	0
48	Validation of the Latin American Spanish version of the face-name associative memory exam in a Colombian Sample. Clinical Neuropsychologist, 2020, 34, 1-12.	1.5	13
49	Association of subjective cognitive decline with markers of brain pathology in preclinical autosomal dominant Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 330-332.	0.9	7
50	Genetic and nongenetic factors associated with CADASIL: A retrospective cohort study. Journal of the Neurological Sciences, 2020, 419, 117178.	0.3	5
51	Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA - Journal of the American Medical Association, 2020, 324, 772.	3.8	640
52	Examining Sex Differences in Markers of Cognition and Neurodegeneration in Autosomal Dominant Alzheimer's Disease: Preliminary Findings from the Colombian Alzheimer's Prevention Initiative Biomarker Study. Journal of Alzheimer's Disease, 2020, 77, 1743-1753.	1.2	12
53	The Latin American Spanish version of the Face-Name Associative Memory Exam is sensitive to cognitive and pathological changes in preclinical autosomal dominant Alzheimer's disease. Alzheimer's Research and Therapy, 2020, 12, 104.	3.0	7
54	Visual short-term memory relates to tau and amyloid burdens in preclinical autosomal dominant Alzheimer's disease. Alzheimer's Research and Therapy, 2020, 12, 99.	3.0	22

#	Article	IF	Citations
55	Phosphoâ€ŧau217 and phosphoâ€ŧau181 in plasma and CSF as biomarkers for Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e037520.	0.4	2
56	Association of tau tangle burden with depressive symptoms in communityâ€dwelling older adults: A longitudinal study. Alzheimer's and Dementia, 2020, 16, e038867.	0.4	0
57	PET evidence of preclinical cerebellar amyloid plaque deposition in autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e039051.	0.4	0
58	Evolution of unawareness of memory decline in individuals with autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e039921.	0.4	0
59	Sex differences in neurodegeneration and memory performance in preclinical autosomal dominant Alzheimer's disease: Baseline findings from the API ADAD trial. Alzheimer's and Dementia, 2020, 16, e041225.	0.4	1
60	Evaluating preâ€screening tools for older Latino recruitment into preclinical Alzheimer's disease studies. Alzheimer's and Dementia, 2020, 16, e041571.	0.4	0
61	Longitudinal hippocampal atrophy is associated with an amyloidâ€independent entorhinal tauopathy and an amyloidâ€dependent neocortical tauopathy. Alzheimer's and Dementia, 2020, 16, e045733.	0.4	1
62	Associations between physical activity and markers of brain pathology in autosomal dominant Alzheimer's disease: A preliminary report. Alzheimer's and Dementia, 2020, 16, e045857.	0.4	0
63	Sex differences in body composition in nonâ€demented individuals with autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e046226.	0.4	0
64	Reduced thalamic volume is associated with early brain pathology in preclinical autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e046347.	0.4	0
65	Depressive symptoms are associated with hippocampal neurodegeneration in preclinical autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e046495.	0.4	0
66	Association of tau tangle burden with depressive symptoms in communityâ€dwelling older adults: A longitudinal study. Alzheimer's and Dementia, 2020, 16, e046549.	0.4	0
67	Longitudinal increase in depressive symptoms in relation to neurodegeneration in clinically normal older adults: Findings from the Harvard Aging Brain Study. Alzheimer's and Dementia, 2020, 16, e047321.	0.4	0
68	0421 Decreased Actigraphic Daytime Activity is Associated with Lower Memory Performance in Cognitively-Unimpaired Individuals with Autosomal Dominant Alzheimer's Disease. Sleep, 2020, 43, A161-A161.	0.6	0
69	Baseline demographic, clinical, and cognitive characteristics of the Alzheimer's Prevention Initiative (API) Autosomalâ€Dominant Alzheimer's Disease Colombia Trial. Alzheimer's and Dementia, 2020, 16, 1023-1030.	0.4	15
70	Examining Cognitive Decline Across Black and White Participants in the Harvard Aging Brain Study. Journal of Alzheimer's Disease, 2020, 75, 1437-1446.	1.2	18
71	Plasma neurofilament light chain in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional and longitudinal cohort study. Lancet Neurology, The, 2020, 19, 513-521.	4.9	97
72	The INECO Frontal Screening for the Evaluation of Executive Dysfunction in Cerebral Small Vessel Disease: Evidence from Quantitative MRI in a CADASIL Cohort from Colombia. Journal of the International Neuropsychological Society, 2020, 26, 1006-1018.	1.2	5

#	Article	IF	CITATIONS
73	Associative memory and in vivo brain pathology in asymptomatic presenilin-1 E280A carriers. Neurology, 2020, 95, e1312-e1321.	1.5	7
74	Worldâ€Wide FINGERS Network: A global approach to risk reduction and prevention of dementia. Alzheimer's and Dementia, 2020, 16, 1078-1094.	0.4	257
75	Exceptionally low likelihood of Alzheimer's dementia in APOE2 homozygotes from a 5,000-person neuropathological study. Nature Communications, 2020, 11, 667.	5.8	246
76	Trajectory of Unawareness of Memory Decline in Individuals With Autosomal Dominant Alzheimer Disease. JAMA Network Open, 2020, 3, e2027472.	2.8	22
77	Dementia Diagnosis, Treatment, and Care in Colombia, South America. , 2020, , 333-343.		1
78	The impact of amyloidâ€beta and tau on prospective cognitive decline in older individuals. Annals of Neurology, 2019, 85, 181-193.	2.8	171
79	Longitudinal Association of Depression Symptoms With Cognition and Cortical Amyloid Among Community-Dwelling Older Adults. JAMA Network Open, 2019, 2, e198964.	2.8	72
80	Associations of Physical Activity and $\hat{I}^2$ -Amyloid With Longitudinal Cognition and Neurodegeneration in Clinically Normal Older Adults. JAMA Neurology, 2019, 76, 1203.	<b>4.</b> 5	97
81	Neuropsychiatric Symptoms in Parkinson's Disease with and without Mild Cognitive Impairment. Archives of Clinical Neuropsychology, 2019, 34, 1238-1238.	0.3	0
82	Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease. JAMA Neurology, 2019, 76, 915.	4.5	512
83	BIOLOGICAL AND COGNITIVE MARKERS OF PRESENILIN1 E280A AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE: A COMPREHENSIVE REVIEW OF THE COLOMBIAN KINDRED. journal of prevention of Alzheimer's disease, The, 2019, 6, 1-9.	1.5	31
84	Striatal amyloid is associated with tauopathy and memory decline in familial Alzheimer's disease. Alzheimer's Research and Therapy, 2019, 11, 17.	3.0	26
85	Genetic origin of a large family with a novel <i>PSEN1</i> mutation (Ile416Thr). Alzheimer's and Dementia, 2019, 15, 709-719.	0.4	23
86	P4â€607: FREE AND CUED MEMORY IS DISTINCTLY RELATED TO PATHOLOGY IN PRECLINICAL AUTOSOMALâ€DOMINANT ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P1557.	0.4	0
87	F4â€04â€01: TRIAL DESIGN, DATA SHARING RISK MITIGATION, AND BASELINE CLINICAL AND COGNITIVE DATA FR THE API AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE COLOMBIA TRIAL. Alzheimer's and Dementia, 2019, 15, P1222.	OM 0.4	0
88	P4â€608: TAU ACCUMULATION AND VISUAL MEMORY IN COGNITIVELY UNIMPAIRED PSEN1 E280A MUTATION CARRIERS. Alzheimer's and Dementia, 2019, 15, P1557.	0.4	0
89	Resistance to autosomal dominant Alzheimer's disease in an APOE3 Christchurch homozygote: a case report. Nature Medicine, 2019, 25, 1680-1683.	15.2	328
90	ICâ€Pâ€058: COVARYING SPATIAL PATTERNS OF TAU DEPOSITION AND GRAY MATTER ATROPHY UNEARTHED BY THE INFORMED MULTIMODAL PARTIAL LEAST SQUARES (MMPLS) IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE: FINDINGS FROM THE COLBOS PROJECT. Alzheimer's and Dementia, 2019, 15, P58.	0.4	O

#	Article	IF	CITATIONS
91	O3â€09â€01: PROTECTIVE EFFECT OF PHYSICAL ACTIVITY ON LONGITUDINAL COGNITIVE DECLINE AND NEURODEGENERATION IN CLINICALLY NORMAL OLDER ADULTS WITH ELEVATED βâ€AMYLOID BURDEN. Alzheimer's and Dementia, 2019, 15, P903.	0.4	O
92	Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: Update and areas of immediate need. Alzheimer's and Dementia, 2019, 15, 292-312.	0.4	310
93	Event-related potential correlates of recognition memory in asymptomatic individuals with CADASIL. Brain Research, 2019, 1707, 74-78.	1.1	3
94	Clinical and research applications of magnetic resonance imaging in the study of CADASIL. Neuroscience Letters, 2019, 698, 173-179.	1.0	27
95	Dynamic Causal Modeling of Preclinical Autosomal-Dominant Alzheimer's Disease. Journal of Alzheimer's Disease, 2018, 65, 697-711.	1.2	15
96	Association Between Amyloid and Tau Accumulation in Young Adults With Autosomal Dominant Alzheimer Disease. JAMA Neurology, 2018, 75, 548.	4.5	137
97	ICâ€Pâ€010: COMPARING CEREBRAL WHITE MATTER, CEREBELLAR, AND PONTINE REFERENCE REGIONS TO CHARACTERIZE FLORBETAPIR PET MEASUREMENTS OF AMYLOIDâ€Î² BURDEN IN PSEN1 E280A MUTATION CARRIERS AND NONCARRIERS FROM THE COLOMBIAN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE KINDRED. Alzheimer's and Dementia. 2018. 14. P20.	0.4	O
98	P2â€071: COMPARING CEREBRAL WHITE MATTER, CEREBELLAR, AND PONTINE REFERENCE REGIONS TO CHARACTERIZE FLORBETAPIR PET MEASUREMENTS OF AMYLOIDâ€Î² BURDEN IN PSEN1 E280A MUTATION CARRIERS AND NONCARRIERS FROM THE COLOMBIAN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE KINDRED. Alzheimer's and Dementia, 2018, 14, P694.	0.4	0
99	ICâ€Pâ€139: LONGITUDINAL DEPRESSIVE SYMPTOMS AND CORTICAL AMYLOID ARE ASSOCIATED WITH COGNITI DECLINE IN OLDER ADULTS. Alzheimer's and Dementia, 2018, 14, P116.	VE 0.4	O
100	ICâ€Pâ€140: TAU ACCUMULATION AND MEMORY DECLINE ARE MORE CLOSELY RELATED TO STRIATAL THAN CORTICAL AMYLOIDOSIS IN INDIVIDUALS WITH EARLYâ€ONSET AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P117.	. 0.4	0
101	P2â€461: ENTORHINAL TAU PATHOLOGY IS ASSOCIATED WITH WHITE MATTER ABNORMALITIES IN UNCINATE FASCICULUS IN PRECLINICAL AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P897.	0.4	O
102	ICâ€Pâ€147: QUANTIFYING STAGES OF SUBTLE MEMORY IMPAIRMENT IN PRECLINICAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P125.	0.4	1
103	A Three-Factor Structure of Cognitive Functioning Among Unimpaired Carriers and Non-Carriers of Autosomal-Dominant Alzheimer's Disease. Journal of Alzheimer's Disease, 2018, 65, 107-115.	1.2	9
104	Desempeño cognitivo en portadores asintomáticos de las mutaciones R1031C y R141C en CADASIL. International Journal of Psychological Research, 2018, 11, 46-55.	0.3	2
105	P3â€399: ASSOCIATION BETWEEN CORTICAL THINNING AND TAU PATHOLOGY IN PRECLINICAL AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1253.	0.4	O
106	Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid $\hat{l}^2$ . Alzheimer's and Dementia, 2017, 13, 1004-1012.	0.4	139
107	Subjective memory complaints in preclinical autosomal dominant Alzheimer disease. Neurology, 2017, 89, 1464-1470.	1.5	23
108	[P4–243]: ANXIETY, SUBJECTIVE COGNITIVE DECLINE, AND CORTICAL AMYLOID IN PRECLINICAL AUTOSOMAL DOMINANT ALZHEIMER's DISEASE: A PRELIMINARY REPORT. Alzheimer's and Dementia, 2017, 13, P1369.	0.4	0

#	Article	IF	CITATIONS
109	[ICâ€Pâ€089]: ANXIETY, SUBJECTIVE COGNITIVE DECLINE, AND CORTICAL AMYLOID IN PRECLINICAL AUTOSOMA DOMINANT ALZHEIMER's DISEASE: A PRELIMINARY REPORT. Alzheimer's and Dementia, 2017, 13, P72.	L <sub>0.4</sub>	0
110	[P1–434]: RELATIONSHIPS BETWEEN MEMORY FUNCTION, TAU PATHOLOGY AND FUNCTIONAL CONNECTIVIT IN THE DEFAULT MODE NETWORK IN AUTOSOMALâ€ĐOMINANT ALZHEIMER'S DISEASE: A PRELIMINARY REPORT Alzheimer's and Dementia, 2017, 13, P448.		0
111	[O1–13–02]: COGNITIVE VULNERABILITIES IN PRESENILINâ€1 E280A MUTATIONâ€CARRYING CHILDREN FRO WORLD's LARGEST AUTOSOMALâ€DOMINANT ALZHEIMER's DISEASE KINDRED. Alzheimer's and Dementia, 2017, 13, P225.	M THE 0.4	1
112	[F3–05–04]: SOCIOCULTURAL FACTORS AND COGNITIVE IMPAIRMENT IN OLDER LATINOS LIVING IN BOSTO Alzheimer's and Dementia, 2017, 13, P885.	N <sub>Ö.4</sub>	0
113	[P1–030]: RELATIONSHIPS BETWEEN MEMORY FUNCTION, TAU PATHOLOGY AND FUNCTIONAL CONNECTIVIT IN THE DEFAULT MODE NETWORK IN AUTOSOMALâ€DOMINANT ALZHEIMER'S DISEASE: A PRELIMINARY REPORT Alzheimer's and Dementia, 2017, 13, P245.	Y . 0.4	0
114	P3â€309: Profiles of Cognitive Decline Associated with Biomarkerâ€Defined Preclinical Stages of Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P960.	0.4	0
115	P3-322: Optimal Memory Performance in Older Adults is Associated with Differences in Hippocampal Volume and Amyloid Status at Baseline and Over 3 Years. , 2016, 12, P969-P969.		O
116	O4â€01â€02: Tau and Amyloid Pet Imaging in a Colombian Kindred with Autosomalâ€Dominant Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P330.	0.4	0
117	Blood biomarkers in a mouse model of CADASIL. Brain Research, 2016, 1644, 118-126.	1.1	16
118	P1â€⊋79: Faceâ€Name Recognition Memory in Preclinical Autosomalâ€Dominant Alzheimer's Disease: An FMI Study. Alzheimer's and Dementia, 2016, 12, P525.	RI 0.4	0
119	ICâ€Pâ€198: TAU and Amyloid PET Imaging in a Colombian Kindred with Autosomalâ€Dominant Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P143.	0.4	O
120	Cognitive Decline in a Colombian Kindred With Autosomal Dominant Alzheimer Disease. JAMA Neurology, 2016, 73, 431.	4.5	69
121	P4-269: Relationships between baseline biomarkers and subsequent cognitive decline in cognitively unimpaired PSEN1 E280A mutation carriers from the colombian kindred with autosomal dominant Alzheimer's disease., 2015, 11, P888-P888.		1
122	Successful Scene Encoding in Presymptomatic Early-Onset Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 47, 955-964.	1.2	5
123	P3-104: Associations between subjective memory complaints and hippocampal volume in preclinical early-onset Alzheimer's disease., 2015, 11, P660-P661.		O
124	Brain Imaging and Blood Biomarker Abnormalities in Children With Autosomal Dominant Alzheimer Disease. JAMA Neurology, 2015, 72, 912.	4.5	94
125	Associations Between Biomarkers and Age in the Presenilin 1 E280A Autosomal Dominant Alzheimer Disease Kindred. JAMA Neurology, 2015, 72, 316.	4.5	145
126	Ushering in the study and treatment of preclinical Alzheimer disease. Nature Reviews Neurology, 2013, 9, 371-381.	4.9	125

#	Article	IF	CITATIONS
127	Cortical atrophy in presymptomatic Alzheimer's disease presenilin 1 mutation carriers. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 556-561.	0.9	44
128	Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurology, The, 2012, 11, 1048-1056.	4.9	450
129	Florbetapir PET analysis of amyloid- $\hat{l}^2$ deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study. Lancet Neurology, The, 2012, 11, 1057-1065.	4.9	209
130	Charting the path for early diagnosis and prevention of Alzheimer's disease. Expert Review of Neurotherapeutics, 2011, 11, 1665-1667.	1.4	3
131	Alzheimer's Prevention Initiative: A Plan to Accelerate the Evaluation of Presymptomatic Treatments. Journal of Alzheimer's Disease, 2011, 26, 321-329.	1.2	309
132	ERP generator anomalies in presymptomatic carriers of the Alzheimer's disease E280A <i>PSâ€1 </i> mutation. Human Brain Mapping, 2010, 31, 247-265.	1.9	33
133	Hippocampal hyperactivation in presymptomatic familial Alzheimer's disease. Annals of Neurology, 2010, 68, 865-875.	2.8	195